{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:59Z","timestamp":1791335639064,"version":"4.3.1"},"reference-count":107,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances in systemic therapy. While histology remains the most clinically relevant prognostic indicator, the expanding use of immunotherapy and ongoing clinical trials involving targeted therapies have increased interest in the development of predictive and prognostic biomarkers in this disease. This review summarizes the current biologic and therapeutic landscape of PM and the biomarkers that influence prognosis and treatment response. Biomarkers such as programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) demonstrate inconsistent predictive value in PM and are not currently used in clinical decision pathways in the real-world setting. This review highlights the developing role of dynamic biomarkers such as circulating tumor DNA (ctDNA) for molecular response assessment and minimal residual disease (MRD) detection. This review also examines important genomic and transcriptomic alterations in PM, such as MTAP, BAP1, CDKN2A, and NF2\/YAP\/TEAD. These alterations provide potential targets for ongoing early-phase clinical trials. Future advances in PM will depend on the development and integration of comprehensive biomarker models that combine clinicopathologic, immune, and molecular features of this complex and heterogenous disease.<\/jats:p>","DOI":"10.3390\/cancers18040679","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:51:09Z","timestamp":1771491069000},"page":"679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-7851","authenticated-orcid":false,"given":"Logan","family":"Roof","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenna","family":"Koehler","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thorsurg.2020.08.007","article-title":"Pathology of Malignant Pleural Mesothelioma","volume":"30","author":"Hung","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1002\/cam4.5915","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database","volume":"12","author":"Chang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality\u2014United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Brims, F. (2021). Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13164194"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(24)00155-4","article-title":"EPA ruling to ban chrysotile asbestos","volume":"25","author":"Burki","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_7","first-page":"491","article-title":"Malignant pleural mesothelioma: An epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107511","DOI":"10.1016\/j.rmed.2023.107511","article-title":"Comprehensive clinical overview of malignant pleural mesothelioma","volume":"222","author":"Khan","year":"2024","journal-title":"Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification\u2014Update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: A phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.21037\/tlcr-19-485","article-title":"Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma","volume":"9","author":"Brockwell","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brcic, L., Mathilakathu, A., Walter, R.F.H., Wessolly, M., Mairinger, E., Beckert, H., Kreidt, D., Steinborn, J., Hager, T., and Christoph, D.C. (2021). Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers, 13.","DOI":"10.3390\/cancers13081761"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_19","unstructured":"National Comprehensive Cancer Network (2026, January 17). NCCN Clinical Practice Guidelines in Oncology: Pleural Mesothelioma (Version 2.2026). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_pleural.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemona\u00efve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: Results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1513\/AnnalsATS.201506-315LE","article-title":"Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy","volume":"12","author":"Moser","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-5002(00)00217-8","article-title":"Localised spontaneous regression in mesothelioma\u2014Possible immunological mechanism","volume":"32","author":"Robinson","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2007.tb01315.x","article-title":"Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura","volume":"187","author":"Allen","year":"2007","journal-title":"Med. J. Aust."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21357","DOI":"10.1038\/s41598-021-00831-4","article-title":"Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort","volume":"11","author":"Cedres","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: Correlation with clinical\u2013pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Duruisseaux","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., and Felip, E. (2015). Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121071"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Oehl, K., Vrugt, B., Opitz, I., and Meerang, M. (2018). Heterogeneity in malignant pleural mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061603"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2019.06.020","article-title":"Pathologic considerations and standardization in mesothelioma clinical trials","volume":"14","author":"Tsao","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: A series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: Prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1\u2013positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41698-025-00922-9","article-title":"Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers","volume":"9","author":"Lakbir","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated with Immune Checkpoint Inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100925","DOI":"10.1016\/j.mcpro.2025.100925","article-title":"Multiple Classes of Antigen Contribute to the Antigenic Landscape of Mesothelioma","volume":"24","author":"Pandey","year":"2025","journal-title":"Mol. Cell Proteom."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Rwandamuriye, F.X., Redwood, A.J., Creaney, J., and Robinson, B.W.S. (2026). Hidden Targets in Cancer Immunotherapy: The Potential of \u201cDark Matter\u201d Neoantigens. Vaccines, 14.","DOI":"10.3390\/vaccines14010104"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1538-7445.AM2019-1349","article-title":"Personalized circulating tumor DNA profiling in malignant pleural mesothelioma","volume":"79","author":"Martinson","year":"2019","journal-title":"Cancer Res."},{"key":"ref_54","first-page":"100692","article-title":"Individualized Cell-Free DNA Monitoring with Chromosomal Junctions for Mesothelioma","volume":"5","author":"Parikh","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1038\/s41591-025-03958-3","article-title":"Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: A phase 2 trial and ctDNA analyses","volume":"31","author":"Reuss","year":"2025","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"ref_58","unstructured":"ClinicalTrials.gov (2026, January 17). Safety and Tolerability of TNG908 in Patients with MTAP-Deleted Advanced or Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT05275478, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05275478."},{"key":"ref_59","unstructured":"ClinicalTrials.gov (2026, January 17). A Study of AZD3470, a PRMT5 Inhibitor, in Patients with MTAP Deficient Advanced\/Metastatic Solid Tumors (PRIMROSE). ClinicalTrials.gov Identifier: NCT06130553, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06130553."},{"key":"ref_60","unstructured":"ClinicalTrials.gov (2026, January 17). A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants with Advanced Solid Tumors with Homozygous Methylthioadenosine Phosphorylase Deletion. ClinicalTrials.gov Identifier: NCT06672523, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06672523."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107963","DOI":"10.1016\/j.lungcan.2024.107963","article-title":"MTAP as an emerging biomarker in thoracic malignancies","volume":"197","author":"Brune","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: A validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"Rusch","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: Not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.jtho.2018.08.204","article-title":"MS31. 02 clinical implementation of BAP1 inhibitors","volume":"13","author":"Baas","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41388-025-03672-x","article-title":"BAP1-loss in mesothelioma: Molecular mechanisms and clinical opportunities","volume":"45","author":"Fennell","year":"2026","journal-title":"Oncogene"},{"key":"ref_70","unstructured":"ClinicalTrials.gov (2026, January 17). Alrizomadlin (APG-115) in Subjects with BAP1 Cancer Syndrome and Early-Stage Mesothelioma. ClinicalTrials.gov Identifier: NCT06654050, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06654050."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Heged\u00fcs, L., Qaisieh, S., St\u00fclpnagel, C., Ganjeh Khor Dezfouli, Y., Tambo, W., Doerr, F., Baldes, N., Theegarten, D., Schuler, M., and B\u00f6l\u00fckbas, S. (2025). Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression. Cells, 14.","DOI":"10.3390\/cells14201599"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2767-9764.CRC-23-0276","article-title":"Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma","volume":"4","author":"Badhai","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41416-024-02661-3","article-title":"Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma","volume":"130","author":"Landman","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2020.10.020","article-title":"Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre","volume":"150","author":"Marshall","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_80","first-page":"100232","article-title":"Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes","volume":"25","author":"Markowitz","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/humu.20083","article-title":"The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association","volume":"24","author":"Murphy","year":"2004","journal-title":"Hum. Mutat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.18632\/genesandcancer.138","article-title":"Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma","volume":"8","author":"Sobhani","year":"2017","journal-title":"Genes. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2016.34.15_suppl.2528","article-title":"Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4\/6 inhibitor) in the Signature program","volume":"34","author":"Peguero","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"B160","DOI":"10.1158\/1535-7163.TARG-23-B160","article-title":"Abstract B160: A phase 1 open-label, dose-escalation study of central nervous system\u2013penetrant cyclin-dependent kinase (CDK) 4\/6 inhibitor PRT3645 in patients with select advanced or metastatic solid tumors","volume":"22","author":"Patnaik","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","first-page":"75","article-title":"Hippo\/YAP pathway for targeted therapy","volume":"3","author":"Stahel","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Mokhtari, R.B., Ashayeri, N., Baghaie, L., Sambi, M., Satari, K., Baluch, N., Bosykh, D.A., Szewczuk, M.R., and Chakraborty, S. (2023). The hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers, 15.","DOI":"10.3390\/cancers15133468"},{"key":"ref_88","unstructured":"ClinicalTrials.gov (2026, January 17). Study to Evaluate VT3989 in Patients with Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT04665206, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04665206."},{"key":"ref_89","unstructured":"ClinicalTrials.gov (2026, January 17). Study of ISM6331 in Participants with Advanced\/Metastatic Malignant Mesothelioma or Other Solid Tumors. ClinicalTrials.gov Identifier: NCT06566079, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06566079."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages","volume":"11","author":"Chene","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Minnema-Luiting, J., Vroman, H., Aerts, J., and Cornelissen, R. (2018). Heterogeneity in immune cell content in malignant pleural mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041041"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"D\u00e9sage, A.-L., Karpathiou, G., Peoc\u2019h, M., and Froudarakis, M.E. (2021). The immune microenvironment of malignant pleural mesothelioma: A literature review. Cancers, 13.","DOI":"10.3390\/cancers13133205"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Chu, G.J., van Zandwijk, N., and Rasko, J.E.J. (2019). The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01366"},{"key":"ref_97","first-page":"5228","article-title":"Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas","volume":"9","author":"Freedman","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"118357","DOI":"10.1016\/j.ecoenv.2025.118357","article-title":"A four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China","volume":"299","author":"Zhu","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Martinez-Rivera, V., Negrete-Garcia, M.C., Avila-Moreno, F., and Ortiz-Quintero, B. (2018). Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020595"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102547","DOI":"10.1016\/j.tranon.2025.102547","article-title":"The role of non-coding RNAs in pleural mesothelioma","volume":"62","author":"Tonnini","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15287394.2020.1734891","article-title":"MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma","volume":"83","author":"Kim","year":"2020","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102520","DOI":"10.1016\/j.tranon.2025.102520","article-title":"MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial","volume":"61","author":"Levallet","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_105","unstructured":"ClinicalTrials.gov (2026, January 17). ATREUS\u2014Phase II Study on the Activity of Trabectedin in Patients with Malignant Pleural Mesothelioma (MPM) (ATREUS). ClinicalTrials.gov Identifier: NCT02194231, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02194231."},{"key":"ref_106","unstructured":"ClinicalTrials.gov (2026, January 17). MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients with Recurrent MPM and NSCLC. ClinicalTrials.gov Identifier: NCT02369198, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02369198."},{"key":"ref_107","unstructured":"ClinicalTrials.gov (2026, January 17). Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients with Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas. ClinicalTrials.gov Identifier: NCT03233724, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03233724."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:57:41Z","timestamp":1771491461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040679"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040679","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}